Status:
COMPLETED
Possible Role of Gingival Crevicular Fluid Levels of Chemerin and Fibroblast Growth Factor 21 as Biomarkers of Periodontal Disease in Diabetic and Non-diabetic Patients
Lead Sponsor:
Cairo University
Conditions:
Periodontal Disease (Diagnosis)
Diabetes Mellitus, Type 2
Eligibility:
All Genders
35-60 years
Brief Summary
The current study aims to spot the light on the possible role of gingival crevicular fluid (GCF) level of Chemerin and FGF21 to study their potential role as biomarkers of periodontal disease and to u...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- age range between 35 and 60 years
- a minimum of 20 natural teeth.
- Type 2DM patients exhibiting HbA1c 6-8% and FPG ≥126 mg/dL for more than one year who did not complain of any systemic diseases other than t2DM
- periodontitis patients with moderate to severe periodontitis having gingival index GI ≥ 1, probing depth PD ≥ 5, and clinical attachment level CAL ≥ 4 mm, and bone loss affecting \> 30% of existing teeth on clinical/radiographic examination
- Exclusion criteria
- uncontrolled diabetes mellitus
- systemic diseases which may affect the biomarkers levels and the periodontal conditions.
- Exposure to steroid therapies, radiation/immune-suppressive therapies.
- Allergic reaction to any kind of drug.
- Smoking over the past 5 years.
- Periapical pathologies.
- Exposure to mechanical forces as a result of occlusion/ orthodontics.
- History of periodontal or drug therapies within the previous 6 months.
Exclusion
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2018
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04012983
Start Date
March 1 2018
End Date
September 1 2018
Last Update
July 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Dentistry
Cairo, Egypt, 11431